Efalizumab in the treatment of psoriasis: When comorbidity is an issue

Dermatologic Therapy

Volumn 21, Issue SUPPL. 2, 2008, Pages

  Prignano, Francesca ^a   Buggiani, Gionata ^a   Lotti, Torello ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Biologicals; Comorbidity; Efalizumab; Psoriasis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DRUG CONTRAINDICATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATTY LIVER; FEMALE; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNOTHERAPY; LONG TERM CARE; MALE; OBESITY; PSORIASIS; QUALITY OF LIFE; SELF ESTEEM;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11A; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RISK FACTORS; T-LYMPHOCYTES;

EID: 53149114852     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2008.00229.x     Document Type: Article

References (22)

1. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005 : 64 (Suppl. 2 ii18 23 discussion ii24-25.
2. Strange P, Cooper KD, Hansen ER, et al. T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J Invest Dermatol 1993 : 101 : 695 700.
3. Bos JD, Hulsebosh HJ, Krieg SR, et al. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983 : 275 : 181 189.
4. Finch PW, Murphy F, Cardinale I, et al. Altered expression of keratinocyte growth factor and its receptor in psoriasis. Am J Pathol 1997 : 151 : 1619 1628.
5. Kremers HM, McEvoy MT, Dann FJ, et al. Heart disease in psoriasis. J Am Acad Dermatol 2007 : 57 : 347 354.
6. Ludwig RJ, Boehncke WH. Psoriasis and risk of myocardial infarction. JAMA 2007 : 297 : 362 author reply 362-363.
7. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006 : 298 : 321 328.
8. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006 : 55 : 829 835.
9. Mallbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006 : 8 : 355 363.
10. Urpe M, Buggiani G, Lotti T. Stress and psychoneuroimmunologic factors in dermatology. Dermatol Clin 2005 : 23 : 609 617.
11. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007 : 370 : 272 284.
12. Gupta AK, Cherman AM. Efalizumab in the treatment of psoriasis. J Cutan Med Surg 2006 : 10 : 57 68.
13. Selenko-Gebauer N, Karlhofer F, Stingl G. Efalizumab in routine use: a clinical experience. Br J Dermatol 2007 : 156 (Suppl. 2 1 6.
14. Shear NH. Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? Drug Saf 2006 : 29 : 49 66.
15. Alexander E, Pinto J, Pal GS, et al. Disease concomitance in psoriasis: a clinical study of 61 cases. Indian J Dermatol Venereol Leprol 2001 : 67 : 66 68.
16. Sterry W, Strober BE, Menter A on behalf of the International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007 : 157 : 649 655.
17. Leonardi C, Menter A, Hamilton T, et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008 : 158 : 1107 1116.
18. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007 : 156 : 271 276.
19. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007 : 157 : 68 73.
20. Gupta S, Tripathi CD. Current status of TNF blocking therapy in heart failure. Indian J Med Sci 2005 : 59 : 363 366.
21. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006 : 20 : 757 790.
22. Krueger G, Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol 2004 : 140 : 218 225.